Sequanta Technologies
Sequanta Technologies is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 Targeted 4-1BB Ligand) in Combination with Obinutuzumab and in Combination with Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Sponsor Zai Lab (US) LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An Open Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB 11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
Sponsor Beigene Ltd.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Sequanta Technologies?
The 2026-10-09 snapshot links Sequanta Technologies to 12 distinct CTIS trials. Recorded services include Laboratory services, Biomarker testing, RNA extracted from blood and BMA samples. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Sequanta Technologies?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Respiratory. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Sequanta Technologies conducted?
The linked trials record locations in 16 countries, including Spain, Italy, France, Germany, Poland. These are trial locations, not confirmed office locations or countries where Sequanta Technologies delivered services.
What can this page tell me about Sequanta Technologies's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Sequanta Technologies. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Sequanta Technologies Co. Ltd.